Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Malva assurgentiflora

ABSTRACT: Malva assurgentiflora Genome sequencing and assembly

PROVIDER: PRJNA1082754 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR28383136_1.fastq.gz	Fastqsanger.gz
	SRR28383136_2.fastq.gz	Fastqsanger.gz

Items per page:

1 - 2 of 2

Similar Datasets

Malva sylvestris

Project description:Malva sylvestris overview

| PRJNA1246315 | ENA

Malva neglecta

Project description:Malva neglecta overview

| PRJNA1243535 | ENA

Malva sylvestris

Project description:Malva sylvestris Raw sequence reads

| PRJNA952515 | ENA

Malva sylvestris anti-inflammatory activity in oral human cells

Project description:Real-time quantitative PCR analysis of human epithelial cells The activity of Malva sylvestris extract and fractions infected by A. actinomycetemcomitans were investigated using an adapted dual chamber model, oral human epithelial cells were used in the co-culture model. One microgram of RNA was converted in cDNA using RT2 First Strand Kit. 84 genes were analyzed using inflammatory response & Autoimmunity Array RT2 profiler (Qiagen Sabiosciences, Valencia, CA, USA) with buffers supplied by the manufacturer qPCR gene expression profiling. Oral human epithelial cells were infected by A. Actinomycetemcomintans and treated with Malva sylvestris extract and fractions prior to gene expression analysis.

2015-08-27 | E-GEOD-72443 | biostudies-arrayexpress

Malva sylvestris anti-inflammatory activity in oral human cells

2015-08-27 | GSE72443 | GEO

Malva Sylvestris soil microbiome, Morocco

Project description:Malva Sylvestris soil microbiome, Morocco Raw sequence reads

| PRJNA893621 | ENA

Evaluation of Malva Sylvestris. formulation on Radiation proctitis

Project description:Intervention 1: In the intervention group patient should use sachet of Malva, 12 mg in 3 dosage that should brewed in boiled water, from first day of radiation until end of that.(each pocket is 4 g). Intervention 2: All patients in control group take powder of placebo which is designed for this study in 4 mg packets in three dosages a day orally with a glass of hot water.;Prevention;Placebo;In the intervention group patient should use sachet of Malva, 12 mg in 3 dosage that should brewed in boiled water, from first day of radiation until end of that.(each pocket is 4 g);All patients in control group take powder of placebo which is designed for this study in 4 mg packets in three dosages a day orally with a glass of hot water. Primary outcome(s): Anal Burning. Timepoint: Every 3 weeks. Method of measurement: visual analog scale 0-10.;Diarrhea. Timepoint: every 3 week. Method of measurement: visual analog scale 0-10.;Fecal incontinence. Timepoint: every 3 weeks. Method of measurement: visual analog scale.;Fecal urgency. Timepoint: every 3 weeks. Method of measurement: visual analog scale.;Anal bleeding. Timepoint: every 3 weeks. Method of measurement: visual analog scale.;Excretion of mucous. Timepoint: every 3 weeks. Method of measurement: visual analog scale. Study Design: Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Parallel, Purpose: Prevention.

| 2479569 | ecrin-mdr-crc

ddMalNegl

Project description:Malva neglecta

| PRJEB85655 | ENA

ddMalSylv

Project description:Malva sylvestris

| PRJEB87949 | ENA

A multicenter translational biomarker phase II trial of regorafenib in patients with non-resectable pretreated colorectal cancer.

Project description:Primary objectives: The primary objective is to investigate circulating tumor DNA (ctDNA) via deep sequencing for mutation detection and by whole genome sequencing for copy number analyses before start (baseline) with regorafenib and at defined time points during administration of regorafenib for treatment efficacy in colorectal cancer patients in terms of overall survival (OS). Primary endpoints: circulating tumor DNA (ctDNA) via deep sequencing for mutation detection and by whole genome sequencing for copy number analyses before start (baseline) with regorafenib and at defined time points during administration of regorafenib for treatment efficacy in colorectal cancer patients in terms of overall survival (OS).

| 2533916 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data